8-K: Relay Therapeutics Q1 2026 Results: Zovegalisib Advances

Relay Therapeutics reported Q1 2026 financial results, highlighting progress in its zovegalisib program for breast cancer and vascular anomalies, and initiated a Phase 1/2 trial for RLY-8161.

Summary

• Relay Therapeutics announced its first quarter 2026 financial results and provided corporate updates.
• The company received FDA Breakthrough Therapy designation for zovegalisib for PIK3CA-mutant, HR+/HER2- advanced breast cancer.
• Phase 3 data for zovegalisib plus atirmociclib in frontline breast cancer is planned for early 2027.
• Initial clinical data for zovegalisib in vascular anomalies is expected on May 19, 2026.
• A Phase 1/2 trial for RLY-8161, an NRAS-selective molecule, has been initiated for NRAS-mutant solid tumors.
• The company ended Q1 2026 with approximately $642 million in cash, cash equivalents, and investments, expecting to fund operations into 2029.
• Revenue for Q1 2026 was $3.0 million, down from $7.7 million in Q1 2025.
• Net loss for Q1 2026 was $73.3 million, an improvement from $77.1 million in Q1 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report due to significant clinical progress, FDA designation, and a strong cash position, despite a revenue decline.

Positives

• FDA Breakthrough Therapy designation granted to zovegalisib for PIK3CA-mutant, HR+/HER2- advanced breast cancer.
• Presented zovegalisib doublet data at ESMO TAT showing 11.1-month median PFS in heavily pre-treated patients.
• Selected zovegalisib plus atirmociclib as the go-forward triplet regimen for 1L breast cancer.
• Phase 3 1L trial in endocrine-sensitive breast cancer patients expected to initiate in early 2027.
• Initiated Phase 1/2 trial of RLY-8161, a NRAS-selective molecule, in patients with NRAS-mutant solid tumors.
• Approximately $642 million in cash, cash equivalents, and investments at the end of Q1 2026, with runway into 2029.
• Net loss improved to $73.3 million in Q1 2026 from $77.1 million in Q1 2025.
• R&D expenses decreased slightly to $70.6 million from $73.8 million year-over-year.

Negatives

• Revenue decreased to $3.0 million in Q1 2026 from $7.7 million in Q1 2025.
• The company reported a net loss of $73.3 million for Q1 2026.

Risks

• The preliminary or interim results of clinical trials may not be predictive of future or final results.
• Interim and early clinical data may change as more patient data become available and are subject to audit and verification procedures.
• Relay Therapeutics' ability to successfully demonstrate the safety and efficacy of its drug candidates.
• The timing and outcome of planned interactions with regulatory authorities.
• Obtaining, maintaining, and protecting intellectual property.
• Impact of global economic uncertainty, geopolitical instability, and public health epidemics on clinical trials and operations.
• Significant political, trade, or regulatory developments beyond the company's control.
• The delay or pause of any current or planned clinical trials or drug candidate development.

Future Outlook

The company expects its current cash, cash equivalents, and investments of approximately $642 million to be sufficient to fund its operating expenses and capital expenditure requirements into 2029. A Phase 3 trial for zovegalisib plus atirmociclib in endocrine-sensitive breast cancer patients is expected to initiate in early 2027.

Management Comments

• We have made important progress so far in 2026, highlighted by promising data supporting further development for the zovegalisib plus atirmociclib triplet combination in frontline breast cancer.
• With initial clinical data in vascular anomalies expected at ISSVA and preparations underway for our planned Phase 3 frontline study in endocrine-sensitive patients with metastatic breast cancer, we are entering a data-rich period for zovegalisib.
• Additionally, RLY-8161, our NRAS-selective molecule, has entered clinical development for patients with NRAS-mutant solid tumors.
• We remain focused on executing across these priorities to bring differentiated therapies to patients.

Industry Context

StockSavvy.ai notes that Relay Therapeutics' focus on precision medicine, particularly with its PI3K inhibitor zovegalisib, aligns with the industry trend of developing targeted therapies for specific genetic mutations in cancer and rare diseases. The company's progress in breast cancer and vascular anomalies, coupled with the initiation of a new trial for an NRAS-selective molecule, demonstrates a diversified approach within the oncology and genetic disease therapeutic areas.

Comparison to Industry Standards

• The median PFS of 11.1 months for zovegalisib doublet in heavily pre-treated, PI3K-mutated, HR+/HER2- metastatic breast cancer patients is competitive within the second-line setting for this patient population, though direct comparisons are challenging due to varying trial designs and patient characteristics.
• The objective response rate (ORR) of 44% for the zovegalisib triplet in median third-line patients with PI3K-mutated, HR+/HER2- metastatic breast cancer, while at unoptimized doses, shows potential efficacy that warrants further investigation in Phase 3 trials.
• The company's cash position of $642 million and projected runway into 2029 is a strong indicator of financial stability compared to many clinical-stage biopharmaceutical companies, enabling continued investment in its pipeline.

Stakeholder Impact

• Shareholders: Potential for future value creation through pipeline advancement, offset by revenue decline and ongoing net losses. Strong cash position provides runway.
• Patients: Potential for new, more effective therapies for advanced breast cancer and vascular anomalies with the development of zovegalisib and RLY-8161.
• Partners (e.g., Pfizer): Continued collaboration on clinical trials, with Pfizer supplying atirmociclib and palbociclib for the planned Phase 3 study.

Next Steps

• Initiate Phase 3 1L trial in endocrine-sensitive breast cancer patients in early 2027.
• Present initial clinical results for zovegalisib in vascular anomalies on May 19, 2026.
• Continue execution of the Phase 3 ReDiscover-2 trial of zovegalisib + fulvestrant.
• Continue execution of the Phase 1/2 ReDiscover trial, advancing triplet cohorts.
• Continue execution of the Phase 1/2 ReInspire trial, evaluating zovegalisib in PI3K-driven vascular anomalies.

Key Dates

Recommendation

The company shows promising clinical development with a key FDA designation and a strong cash position, but the revenue decline and ongoing net losses warrant a cautious 'hold' rating. Further data from ongoing trials and progress on the Phase 3 initiation will be critical for a more definitive recommendation.

Keywords

Relay Therapeutics, Zovegalisib, Breast Cancer, PI3K Inhibitor, Vascular Anomalies, NRAS Inhibitor, RLY-8161, Clinical Trials